FDA Safety Labeling Change Order for ADZYNMA

FDA ordered safety labeling changes for ADZYNMA (Takeda) to update prescribing information.

Source updated: Jun 4, 2026

Primary source: https://www.fda.gov/media/192655/download

PV Impact Brief

Urgency: HighConfidence: high

What changed

FDA ordered safety labeling changes for ADZYNMA to update safety information in the prescribing information.

Why it matters

Updated safety information may include new warnings, precautions, or adverse reactions that impact risk-benefit assessment and signal management.

Action needed

Review the specific labeling changes required by the FDA order and update internal safety documents and signal evaluation for ADZYNMA accordingly.

Relevant for: Regulatory Intelligence LeadSignal Management Lead
Processes impacted: Signal ManagementLabeling
Owner: Regulatory Intelligence Lead
Review cadence: one-time

Regulatory action details

Action type: Safety Labeling Change Order
Publication date: 2026-06-04
Safety issue: Safety labeling changes ordered by the FDA for ADZYNMA to update safety information in the prescribing information.

Affected products

ADZYNMA
Takeda Pharmaceuticals

PV internal implications

Manufacturer must submit labeling supplements with the required changes by the specified deadline.

View regulator source

Evidence and confidence

Confidence: highSource updated: Jun 4, 2026

https://www.fda.gov/media/192655/downloadUpdated June 4, 2026

Full briefing

Practical implication

Review the specific labeling changes required by the FDA order and update internal safety documents and signal evaluation for ADZYNMA accordingly.

The FDA issued a safety labeling change order requiring Takeda Pharmaceuticals to update the prescribing information for ADZYNMA. The manufacturer must submit labeling supplements with the required changes by the specified deadline.

What changed: FDA ordered safety labeling changes for ADZYNMA to update safety information in the prescribing information.

Why it matters: Updated safety information may include new warnings, precautions, or adverse reactions that impact risk-benefit assessment and signal management.

Practical implication: Review the specific labeling changes required by the FDA order and update internal safety documents and signal evaluation for ADZYNMA accordingly.

View original source

Published from the Firecrawl agent regulatory extraction pipeline.

#Safety Signals #Safety Labeling Change Order #FDA #labeling #firecrawl-agent #regulatory-extraction

Related updates for your role

publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead

SOP Impact2 SOPs

Relevant for: Regulatory Intelligence Lead, PV Quality Lead

verifiedRegulatory action: Notice

Read impact briefarrow_forward

publicMedicines and Healthcare products Regulatory Agency (MHRA) · United Kingdom · Updated May 23, 2026

MHRA confirms UK clinical trial safety reporting guidance is effective

Safety lead to: (1) perform a UK-clinical-trial safety reporting gap assessment against MHRA’s effective guidance sections (MedDRA coding; AE/SAE; RSI governance; SUSARs; annual safety reporting; USMs; serious breaches; temporary suspension), (2) update controlled SOPs/WIs and training records to reflect “effective” status as of 28 Apr 2026, and (3) document deviations/gaps and open CAPA where needed for ongoing UK trials and new submissions.

ICSRCountry ComplianceRegulatory Intelligence Lead

SOP Impact4 SOPs

Relevant for: Regulatory Intelligence Lead, QPPV

verifiedRegulatory action: Guidance

Read impact briefarrow_forward

publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead

SOP Impact2 SOPs

Relevant for: Regulatory Intelligence Lead, Signal Management Lead

verifiedRegulatory action: Agenda

Read impact briefarrow_forward

publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead

SOP Impact1 SOPs

Relevant for: Regulatory Intelligence Lead, PV Quality Lead

verifiedRegulatory action: Checklist

Read impact briefarrow_forward